ReviewImmunotherapy2022
A global picture: therapeutic perspectives for COVID-19.
Review in Immunotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.International journal of molecular sciences · 2022Pooled it
- Investigating apoptosis in peripheral blood mononuclear cells among the elderly in the post-COVID-19 era.BMC immunology · 2025Article
- Classification of Individuals With COVID-19 and Post-COVID-19 Condition and Healthy Controls Using Heart Rate Variability: Machine Learning Study With a Near-Real-Time Monitoring Component.Journal of medical Internet research · 2025Article
- Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.BMC nephrology · 2025Article
- The relationship between ferroptosis and respiratory infectious diseases: a novel landscape for therapeutic approach.Frontiers in immunology · 2025Review
- Transforming health care systems towards high-performance organizations: qualitative study based on learning from COVID-19 pandemic in the Basque Country (Spain).BMC health services research · 2024Article
- Prevalence and prognostic implications of myocardial injury across different waves of COVID-19.Frontiers in cardiovascular medicine · 2024Article
- Ecological comparison of six countries in two waves of COVID-19.Frontiers in public health · 2024Article
- Association of Serum Potassium Variability With 60-day Mortality and Cardiovascular Events after COVID-19 Infection in Maintenance Hemodialysis Patients.International journal of medical sciences · 2024Article
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
- The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution.Heliyon · 2023Article
- Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.International journal of molecular sciences · 2023Article
- Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.Biomolecules · 2023Review
- Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.Process biochemistry (Barking, London, England) · 2023Review
- Links between Vitamin K, Ferroptosis and SARS-CoV-2 Infection.Antioxidants (Basel, Switzerland) · 2023Review
- Review
- Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants.Vaccines · 2023Review
- A mixed methods study exploring requests for unproven COVID therapies such as ivermectin and healthcare distrust in the rural South.Preventive medicine reports · 2023Article
- Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MFrontiers in cellular and infection microbiology · 2023Article
- Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global economy. The most vital part of the research and development of therapeutic agents is to design drug products to manage COVID-19 efficiently. Numerous attempts have been in place to determine the optimal drug dose and combination of drugs to treat the disease on a global scale. This article documents the information available on SARS-CoV-2 and its life cycle, which will aid in the development of the potential treatment options. A consolidated summary of several natural and repurposed drugs to manage COVID-19 is depicted with summary of current vaccine development. People with high age, comorbity and concomitant illnesses such as overweight, metabolic disorders, pulmonary disease, coronary heart disease, renal failure, fatty liver and neoplastic disorders are more prone to create serious COVID-19 and its consequences. This article also presents an overview of post-COVID-19 complications in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.